Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Jiang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9845-2619; OpenAlex author ID A5100325218. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: 4 papers

Papers 12

  1. Emerging roles of the solute carrier family in pancreatic cancer. Co-author DOI 10.1002/ctm2.356↗
  2. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  3. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  4. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.674897↗
  5. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Co-author DOI 10.1186/s12943-020-01167-9↗
  6. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  7. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. Co-author DOI 10.1016/j.ejso.2019.01.018↗
  8. The microbiota and microbiome in pancreatic cancer: more influential than expected. Co-author DOI 10.1186/s12943-019-1008-0↗
  9. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40425-019-0703-0↗
  10. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.7150/jca.29898↗
  11. Critical role of oncogenic KRAS in pancreatic cancer (Review). Co-author DOI 10.3892/mmr.2016.5196↗
  12. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.02.014↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 12 shared papers, 2015–2021 · strength 1.20
  2. Si Shi · 12 shared papers, 2015–2021 · strength 1.20
  3. Jin Xu · 11 shared papers, 2015–2021 · strength 1.07
  4. Jie Hua · 9 shared papers, 2019–2021 · strength 0.97
  5. Chen Liang · 8 shared papers, 2016–2021 · strength 0.83
  6. Qingcai Meng · 7 shared papers, 2019–2021 · strength 0.78
  7. Bo Zhang · 5 shared papers, 2019–2021 · strength 0.59
  8. Miaoyan Wei · 4 shared papers, 2019–2021 · strength 0.43
  9. Yiyin Zhang · 4 shared papers, 2019–2020 · strength 0.40
  10. Wei Wang · 3 shared papers, 2021 · strength 0.38
  11. Quanxing Ni · 4 shared papers, 2015–2019 · strength 0.29
  12. Zhen Tan · 2 shared papers, 2020–2021 · strength 0.24
  13. Liang Chen · 1 shared paper, 2021 · strength 0.13
  14. Zijian Wu · 1 shared paper, 2021 · strength 0.13
  15. Rong Tang · 1 shared paper, 2021 · strength 0.12
  16. Xiaomeng Liu · 1 shared paper, 2021 · strength 0.12
  17. Heng Zhu · 1 shared paper, 2020 · strength 0.11
  18. Jin Peng He · 1 shared paper, 2019 · strength 0.10
  19. Lei Zheng · 1 shared paper, 2019 · strength 0.10
  20. Liang Liu · 2 shared papers, 2015–2016 · strength 0.10
  21. Wenyan Xu · 2 shared papers, 2015–2016 · strength 0.10
  22. Chen Liu · 2 shared papers, 2015–2016 · strength 0.10
  23. Shunrong Ji · 2 shared papers, 2015–2016 · strength 0.10
  24. Yi Qin · 2 shared papers, 2015–2016 · strength 0.10
  25. Miao-Yan Wei · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.